Gemii Technologies Invited to Speak at the 7th Future Healthcare 100 Summit 2023 on Digital Pharma Marketing

The 7th Future Healthcare Top 100 Conference, themed “No Boundaries,” was hosted by VCBeat and VBInsight, in strategic partnership with Shanghai Zhangjiang Group. Held from May 5–7, 2023, at the Shanghai Zhangjiang Science Hall, the conference integrated cutting-edge academic research insights, comprehensive industry perspectives, and keen awareness of capital trends. It brought together industry peers to explore the innovative future of the broader healthcare sector and embark on a new journey in medical innovation.

After six successful editions, the conference has become China’s largest and most information-rich ecosystem event fostering integration between industry and capital in the medical and health innovation sector. Centered on “connecting global wisdom, sharing cutting-edge technologies, inspiring the technological future, and focusing on venture capital interaction,” it sets the direction for innovation and investment in China’s healthcare field. The 7th Future Healthcare 100 Conference in 2023 will feature three major summits, more than 20 thematic forums across specialized sectors, release the Future Healthcare 100 series rankings and awards, publish over ten series reports, and host seven concurrent networking events. Distinguished guests and attendees—including government agencies, academicians and scientists, research and clinical experts, Fortune 500/listed companies, top-tier investment institutions and securities firms, and innovative healthcare enterprises—will gather for this intellectual exchange to inspire the industry and usher in a new future.

“Ask only of courage, ask only of blooming; ask not of west or east” makes a powerful arrival!

As measures such as centralized drug procurement, national reimbursement drug list (NRDL) negotiations, and the “two-invoice system” become standardized, the pharmaceutical distribution market is being reshaped. This transformation is transmitting upstream, driving changes in pharmaceutical companies’ marketing strategies and creating an urgent demand for more cost-effective and efficient marketing approaches. Since 2020, digital marketing in the pharmaceutical industry, led primarily by domestic enterprises, has entered a phase of accelerated growth. By 2022, numerous suppliers from both within and outside the industry had begun to make strategic moves in this area; in February, Omnicom Group Inc., the world’s largest advertising and public relations company, announced its acquisition of Propeller. Digital marketing by pharmaceutical companies is deepening, extending beyond physician outreach and education to encompass patient management. Currently, viewed from the perspective of the entire pharmaceutical marketing industry, digital marketing in China’s pharmaceutical sector remains in its early stages, with the industry still focused on data accumulation and maintaining existing customer bases.

Against this backdrop, the Future Healthcare Top 100 Conference will host a Pharmaceutical Digital Marketing Forum, inviting industry experts, leading enterprises, and investment institutions to comprehensively discuss key issues such as the digital transformation of pharmaceutical marketing, capital allocation strategies, methods for sustaining growth trajectories in pharmaceutical marketing, and the future development opportunities for China’s pharmaceutical digital marketing industry.

Jingli Technology has been deeply engaged in the WeChat ecosystem for seven years, serving thousands of hospitals and over 1.8 million patients to date. It has grown into a leading expert in private-domain solutions within the healthcare industry, boasting unparalleled capabilities in large-scale operations. Leveraging a digital service system grounded in medical evidence-based practices, intelligent product tools, and an excellent service and quality control framework, Jingli Technology gains deep insights into patient needs and pioneered a multi-touchpoint follow-up product.Mr. Yu Junfeng, Vice President of Jingli Technology and Head of the Medical Business Division, was invited to attend this forum and deliver a keynote speech. He will share insights on how multi-touchpoint follow-up can effectively improve medication adherence, empowering innovative thinking for industry integration.